Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma [Phase 2]

View source ↗

Summary

Phase II study evaluating pembrolizumab in combination with mitotane for advanced adrenocortical carcinoma has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• Mitotane (mitotane)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Adrenocortical Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-06-19